Helicobacter pylori infection and increased diabetes prevalence were the risks of colorectal adenoma: a systematic review and meta-analysis

Horng-Yuan Wang

Mackay Memorial Hospital

Ying-Chun Lin

Mackay Memorial Hospital

Chieh-Chang Chen

National Taiwan University Hospital Yun Lin Branch

Ming-Jen Chen

Mackay Memorial Hospital

Ming-Shiang Wu

National Taiwan University

Chun-Jen Liu

National Taiwan University Hospital

Chun-Ta Huang

Mackay Memorial Hospital

Horng-Woei Yang

Mackay Memorial Hospital

Shou-Chuan Shih

Mackay Memorial Hospital

Lo-Yip Yu

Mackay Memorial Hospital

Yang-Che Kuo

Mackay Memorial Hospital

Kuang-Chun Hu (✉ mimiandbear2001@yahoo.com.tw)

Mackay Memorial Hospital <https://orcid.org/0000-0001-7127-4015>

Research article

Keywords: Helicobacter pylori, Diabetes prevalence, colorectal adenoma

Posted Date: October 15th, 2019

DOI: <https://doi.org/10.21203/rs.2.11064/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background *Helicobacter pylori* (*H. Pylori*) infection and hyperglycemia may be associated with an increased risk of colorectal neoplasm. However these two factors affect colorectal neoplasm remain controversial. We aimed to carry out a meta-analysis to evaluate the study population diabetes prevalence rate and *H. pylori* infection rate with colorectal adenoma risk. **Methods** We conducted a systemic research through English databases for medical reports. We also recorded the diabetes prevalence and *H. pylori* infection prevalence in each study. We classified these studies into 4 subgroups as their background population diabetes prevalence < 6%(Group 1); between 6 to 8%(Group 2); between 8 to 10 %(Group 3) and more than 10%(Group 4). The random effects model had used to calculate pooled prevalence estimates with 95% confidence interval [CI]. **Results** Twenty seven studies were finally eligible for meta-analysis. The random-effects model of meta-analysis was chosen, showing pooled odds ratio (OR) equal to 1.51 (95 % CI 1.39–1.63). The subgroup meta-analyses showed in Group 1 the *H. pylori* infection associated colorectal adenoma risk OR was 1.24 (95 % CI 0.86–1.78). As diabetes rate exceed 6%, the *H. pylori* infection became more significant increased risk of colorectal adenoma (Group 2: OR 2.16 (95 % CI 1.61–2.91); Group 3: OR 1.40 (95 % CI 1.24–1.57); Group 4: OR 1.52 (95 % CI 1.46–1.57)). **Conclusions** The results of this meta-analysis showed DM prevalence would affect the risk factor of colorectal adenoma with *H. pylori* infection.

Background

Helicobacter pylori (*H. pylori*) is a Gram-negative bacterium that has infected almost 50% of the world's population[1]. Since 1994, *H. pylori* has been recognized as a human carcinogen by the International Agency for Research on Cancer due to its strong correlation with gastric cancer [2]. Except for intragastric malignancy disease, many scientists have noted that this bacterium is also related to colon neoplasms and colorectal carcinoma (CRC) formation and have shown that infection with *H. pylori* confers a 1.3-1.97-fold increased risk of colon adenoma or adenoma with high-grade dysplasia in the past two decades [3-5]. However, some Asian studies did not show consistent results. Early studies showed that *H. pylori* infection may have a trend of increased colon adenoma but no significant difference [6,7]. Recent studies have demonstrated a positive association between *H. pylori* infection and colon adenoma formation [8,9]. In these studies, Sonnenberg and Genta [3] established the largest study, which included 156,000 patients, and showed that *H. pylori* gastritis was positively associated with colon adenomas (odds ratio (OR) = 1.52). Even with this impressive study result, Plummer also commented and queried several key points [10]. The most important question that needs to be answered is how to explain why some areas had a high prevalence of *H. pylori* infection but a low CRC risk. Several meta-analysis studies have shown that *H. pylori* infection increases the risk of colorectal neoplasm formation[11-13]. However, these studies did not address Plummer's query.

Diabetes mellitus type 2 (DM) is one of the most common metabolic disorders in the world, and the prevalence of DM has been increasing quickly in recent decades [14]. The prevalence of DM also has significant regional variability. According to the latest report, the highest prevalence of DM was found in North America and the Caribbean region, and the prevalence in this region was approximately 11.0%. The Western Pacific region (including Australia, China, Indonesia, Japan, Taiwan, Korea and Vietnam) has a DM prevalence of approximately 8.1% [15]. However, as socioeconomic growth and industrialization are rapidly occurring in this area, the increasing prevalence of diabetes was also noted in these countries[16]. DM is also considered a risk factor for colon adenoma and carcinoma. Several studies have shown that subjects with DM had an OR of 1.45 for colon adenoma and a relative risk of 1.38 for colorectal adenocarcinoma[17, 18]. Our previous study demonstrated that combined hyperglycemia and *H. pylori* infection was involved in colon adenoma formation and had a synergistic effect[19]. The risk of colorectal adenoma might decrease after *H. pylori* is successfully eradicated[20]. This means that hyperglycemia and *H. pylori* infection might interact and affect colorectal adenoma formation.

Therefore, we carried out a systematic review and meta-analysis of published studies to evaluate the association between *H. pylori* infection and colorectal adenoma formation. Furthermore, we surveyed the DM prevalence in each published study as a subgroup analysis and tried to determine the relationship between *H. pylori* infection and DM prevalence in the risk of colon adenoma formation. We tried to use different DM prevalence rates to classify subgroups of these studies to answer Plummer's question and discuss the relationship between the DM prevalence rate and *H. pylori* infection involvement in colorectal adenoma formation.

Methods

Data sources and searches

PRISMA statement guidelines were followed for conducting and reporting meta-analysis data. The PICOS scheme was followed for reporting inclusion criteria. A systematic search was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane Library for medical reports published until the end of October 2017 without language or date restrictions. The following search terms were used: "*Helicobacter pylori*" AND ("colorectal" OR "colonic" OR "colon" OR "large intestine") AND ("neoplasms" OR "polyp" OR "adenoma" OR "cancer"). Abstracts of articles from the literature search were individually evaluated independently for possible inclusion by the three authors (Chen MJ, Wu MS and Yang HW). For all databases, the last search was run on 22 October 2017.

Study selection

The eligible studies enrolled in the meta-analysis satisfied the following criteria: (i) English-language abstract; (ii) full manuscript publication; (iii) study design: clinical trials including cohort studies, cross-sectional studies and case-control studies; (iv) reported OR estimates with corresponding 95% confidence intervals (CIs) for the relationship between *H. pylori* and colorectal adenoma or provided sufficient raw data to calculate crude ORs and 95% CIs; and (v) results: the prevalence of patients with colorectal adenoma due to *H. pylori* infection or the risk of colorectal adenoma in *H. pylori* infection. Studies were

excluded if they (i) reported duplicate results that were published in other articles, (ii) investigated only the gastrin level or the recurrence of colorectal neoplasia, or (iii) included a pediatric population.

Data extraction

Three reviewers (Chen CC, Liu CJ, Shih SC) independently extracted data by using a predefined form, and disagreements were resolved by discussion and consensus. Information was collected in each selected study as possible, concerning first author, publication year, research type, publication type, the number of subjects, the country of origin, the prevalence of DM rate of origin, the matching variables, the location of neoplasia, the *H. pylori* detection method, the sample characteristics (age and sex), the reported OR for colorectal adenoma with 95% CIs and the covariates adjusted for in the analysis.

Statistical analysis

Three reviewers (Lin YC, Yu LY, Kuo YC) independently assessed the quality of all eligible studies using the ROBINS I scale. The ORs were collected for analysis. Heterogeneity between studies was assessed using both the χ^2 test with a p -value < 0.10 and inconsistency index (I²) with a cut-off of 50%. Pooled effects with 95% CIs were derived using a fixed effect model unless significant heterogeneity was present, in which case a random effects model was applied. When a study provided different OR estimates based on hospital-based controls and population-based controls, the latter estimates were selected for the combined analysis. We also calculated and presented a summary of the adjusted ORs for the studies that provided adjusted results. Publication bias was evaluated with funnel plot and Egger's test.

We examined the roles of several potential sources of heterogeneity using restricted maximum likelihood-based random-effects meta-regression analysis and subgroup analyses according to geographic location, prevalence of diabetes (DM) rate, prevalence of *H. pylori* infection rate, study design, sample size for the cases, subsite of the neoplasia, *H. pylori* detection method and sex. The estimated DM prevalence rate of each study was referenced from the International Diabetes Federation (IDF) Atlas and local country government data or study results (by Wang HY, Huang CT). We used the mean year of study duration as the DM prevalence rate. According to the diabetes prevalence rate of the study population, we classified the studies to 4 groups: group 1: DM prevalence < 6%; group 2: DM prevalence from 6 ~ 8%, group 3: DM prevalence from 8 ~10% and group 4: DM prevalence > 10%. Statistical analyses were performed by STATA version 11.0 (STATA Corporation, College Station, TX, USA) and RevMan version 5.3 (The Cochrane Collaboration, Oxford, UK).

Results

After initial screening, the full text of 281 potentially eligible articles was retrieved for detailed assessment, and 27 studies were eligible for analysis [3,6,8,9,19, 21-42]. All of the eligible studies presented OR for colorectal adenoma related to *H. pylori* infection. [3,6,8,9,19, 21-42] Nineteen of them are cross-sectional studies [3, 6, 8, 19, 21-24, 25-28, 30, 31, 35, 37-40], and the remaining eight are case-control studies [9, 29, 32-34, 36, 41, 42]. Serology was utilized as the detection method for *H. pylori* in 14 studies [8, 9, 21, 23, 25-27, 31-35, 38, 39], pathology in 4 [3, 22, 40, 42], UBT in 4 [6, 37], CLO in 6 [19, 24, 30, 36], and combining UBT and CLO in 2 [28, 29]. Gender and age are reported in 22 [3,6,8,9,19, 21-30, 34-40] and 27 [3,6,8,9,19, 21-35,37-39,41,42] studies respectively. Most studies were carried out in Asia (7 in Korea, 3 in Taiwan, 3 in Japan, 1 in Thailand and 1 in China) and the remaining in Americas (5 in USA and 1 in Brazil) and in Europe (2 in Germany, 1 in Turkey, 1 in Greece and 1 in Israel). All included studies had assessed the quality of all eligible studies using the ROBINS I scale and no serious risk of bias after survey (in Appendix).

A flow chart describing the process of study selection is shown in Figure 1. For the meta-analysis, data were extracted from twenty-seven studies with a total of 68,410 patients, and the pooled OR for colorectal adenoma related to *H. pylori* infection was 1.51 (95% CI 1.39–1.63), although there was significant heterogeneity ($p < 0.001$) (Table 1 and Figure 2). Because of geographic and time differences in DM prevalence rate [43-52], subgroup analysis for the studies was performed by classifying them into 4 groups: group 1: DM prevalence < 6%; group 2: DM prevalence from 6 ~ 8%, group 3: DM prevalence from 8~10% and group 4: DM prevalence > 10% (Table 1 and Figure 2).

In the subgroup analysis, the background population DM prevalence < 6% studies had three studies with a total of 886 patients. Meta-analysis of these studies revealed that the *H. pylori*-infected patients have an increased risk of having colorectal adenoma with a pooled OR of 1.24 (95% CI 0.86–1.78) but no significant difference. There was no significant heterogeneity in group 1 studies ($p = 0.279$). Since the study background population DM prevalence increased more than 6%, the *H. pylori*-infected patients have significant increased risk of having colorectal adenoma. This upturn was more significant when the background population DM prevalence was approximately 6% to 8%. After meta-analysis of these studies, the *H. pylori*-infected people had a higher risk of colorectal adenoma than noninfected people. The pooled OR was 2.16 (95% CI 1.61–2.91), and a total of 11655 patients were included. In these studies, Lin's study noted the DM prevalence in his study participants, and males had an 8.1% prevalence of DM, and females had a 6.1% prevalence of DM. Due to Lin's study population, 6.94% of patients had DM and were thus classified into group 2 for subgroup analysis. There was significant heterogeneity in the group 2 studies ($p < 0.01$).

In groups 3 and 4, similar results were observed. Compared to that of group 2 studies, the pooled OR of groups 3 and 4 was mildly decreased but still had a significantly elevated risk of colorectal adenoma in *H. pylori*-infected patients. For the *H. pylori*-infected patients, the risk of colorectal adenoma in group 3 was 1.40 (95% CI 1.24–1.57), and the group 4 OR was 1.52 (95% CI 1.46–1.57). The group 3 studies included 28,431 patients, and the heterogeneity across studies was marginal ($I^2 = 58.6\%$, $p = 0.013$). There were 27,438 participants included in group 4 studies, and there was no significant heterogeneity ($I^2 = 0.0\%$, $p = 0.704$). We also checked other variables, including gender, detection methods of *H. pylori* infection and study designs, and there was no evidence of statistical relevance to OR for adenoma with *H. pylori* infection.

Test of Heterogeneity and Publication Bias

Heterogeneity was assessed by chi-square and I-square for the included studies. The value of χ^2 was < 0.01 , and the I^2 was 61.9%. Due to the heterogeneity noted in our analysis, a random effects model was used. The shape of the funnel plots for studies on the association between *H. pylori* infection and the risk of colorectal adenoma appeared asymmetrical (Figure 3A), which indicated that studies with positive correlation are reported more often. The *p*-value for Egger's linear regression method ($p < 0.01$) suggested that there was statistical evidence of publication bias. (Figure 3 B)

Discussion

Since the discovery of *H. pylori* as a cause of peptic ulcer disease in 1983, this bacterial infection continues to be a major public health issue worldwide. The prevalence of *H. pylori* infection varies by geographic area, age, ethnicity and socioeconomic status; in fact, the prevalence is higher in developing countries and in those in poor socioeconomic conditions [53]. Traditionally, Western and Eastern countries have different *H. pylori* infection rates in their general populations. The prevalence is highest in Africa (79.1%), Latin America and Asia (54.7%). On the other hand, the *H. pylori* infection rate is lowest in Northern America (37.1%) and Oceania (24.4%)[54,55].

H. pylori infection is the main cause of chronic gastritis and peptic ulcer disease and is the main carcinogen for gastric malignancy disease[56]. In the extragastric system, *H. pylori* infection has also been reported to be related to inflammatory bowel disease, colorectal neoplasms, and cardiovascular disease; to contribute to insulin resistance, associated metabolic syndrome, diabetes, autoimmune disease, and kidney disease; and to be associated with neurodegenerative disease, respiratory disease and hematologic disease [57,58]. In these studies, most scientists addressed the topic of *H. pylori* infection related to colorectal neoplasm formation[3,6,8,9,19, 21-42].

Now that it is known that *H. pylori* is an infectious disease, it can be cured with a course of antibiotics. In recent studies, *H. pylori* infection rate decreased due to public health improvement in developed countries and some developing countries. In many countries, the incidence of *H. pylori* infection has been decreasing in association with improved standards of living and levels of hygiene. However, as the prevalence rate of *H. pylori* infection remains high in most developing countries and is generally related to socioeconomic status, it remains one of the most important diseases in these areas[55]. Hong et al. published a meta-analysis of *H. pylori* infection and increased the risk of colorectal adenoma formation. In this study, he focused on Eastern or Western studies for subgroup analysis and found that the ORs of these two groups were similar[25]. This means that even the *H. pylori* infection prevalence was different in Eastern and Western countries, and this bacterial infection still increased colorectal adenoma formation. Although the detail mechanism of the relation between *H. Pylori* infection and colorectal adenoma formation was not clear. Butt J. stated *H. pylori* infection might contribute to colorectal carcinogenesis by direct or indirect effect. In direct effect, *H. pylori* might secrete toxins and present in the respective colorectal tissue. On the other hand, the indirect effect included several hypotheses. First, *H. pylori* infection could lead to changes in the colonization of the gut with other bacteria and then could induce colorectal carcinogenesis. Second, the gastrin level might increase after *H. pylori* infection and gastrin might act as mitogen. Third, *H. pylori* was found to be associated with metabolic diseases that associated with CRC risk. [59]

It also hints to a link between *H. pylori* infection and colorectal adenoma formation, which may be due to the third factor in this connection.

Unlike *H. pylori* infection disease, the prevalence of DM in the global world has persisted. The age-standardized DM prevalence increased from 4.3% in 1980 to 9.0% in 2014 in men and from 5.0% to 7.9% in women [60]. The rise in prevalence might be due to population growth and aging, as the number of adults with diabetes has increased nearly 4-fold over the past 35 years. The prevalence and number of adults with diabetes both increased and doubled in men and increased by 60% in women worldwide, shifting from an excess prevalence in women in 1980 to a higher male prevalence in 2014[61]. Persistent high blood sugar concentrations lead to damage to the blood vessels and peripheral nerves. This situation might result in an increased risk of cardiovascular diseases, such as heart attack and stroke, kidney disease, diabetic retinopathy and foot amputations [62]. DM is also considered an increased risk factor for colon adenoma and carcinoma [63]. These DM-related complications lead to higher costs for the health care system [64] as well as lower quality of life and reduced life expectancy [65].

A past study showed that DM prevalence was low in much of Asia and sub-Saharan Africa in the 1980s and 1990s [57,66]. However, several recent reports have demonstrated that the DM prevalence has increased in China, India, Turkey and Saudi Arabia [67-70]. Some high-income English-speaking countries, such as the USA and the UK, [71,72] also reported increased DM prevalence. On the other hand, DM prevalence did not increase in Western Europe, and some reports from Sweden, Germany and Switzerland showed similar results [73,74]. In accordance with a previous statement and based on geographical distribution, the prevalence of *H. pylori* infection and DM seems to be inversely related. In our study, when the background population DM prevalence was below 6%, *H. pylori* infection did not significantly increase the risk of colorectal adenoma formation (Group 1). This association became significant when the study population DM prevalence was over 6% (Group 2-4). The odds ratio of *H. pylori* infection-related colorectal formation was 2.16 (95% CI 1.61–2.91); it was the highest when the population DM prevalence was from 6~8% (Group 2). However, when the DM prevalence rate was elevated to 8~10% or more than 10% (Group 3, Group 4), the OR was mildly decreased to 1.40 (95% CI 1.24–1.57) and 1.52 (95% CI 1.46–1.57). *H. pylori* infection still significantly increased colorectal adenoma but was not distinct from Group 2 (DM prevalence between 6 and 8%). However, when DM prevalence increased, *H. pylori* infection might increase the risk of colorectal adenoma formation.

The cause of this condition may be related to the study period and location. Most studies in group 2 were carried out from 1996 to 2000, and group 3 studies were carried out from 2000 to 2010. The study's location may also affect this result. Most of the Group 3 studies were from Korea, and Group 4 studies were from the USA. The Group 2 studies were more heterogeneous in location, including Japan, Taiwan, Turkey, Israel and Germany. The *H. pylori* infection rate of the study population was also collected and is shown in Table 1. There was no significant difference in the ORs of *H. pylori* infection-associated colorectal

adenoma between the lower infection rate area (USA or Germany, 35.3% to 35.6%) and the middle infection rate area (Japan, Korea, China, Taiwan; approximately 51.7% to 55.8%). Further evaluation for the other reason that Group 2 studies revealed higher ORs in *H. pylori* infection-associated colorectal adenoma is necessary. In addition, our study might partially answer Plummer's query "How to explain that some areas had a high prevalence of *H. pylori* infection but low CRC risk?" [10] According to our study, we could see that Brazil et al. had a higher *H. pylori* infection prevalence (71.2%) but a lower DM prevalence rate (5.8%). (Table 1) Buso's study demonstrated that the *H. pylori* infection proportion did not significantly increase colorectal adenoma risk (OR: 1.98, 95% CI 0.82-3.15). [34] However, when the DM prevalence was higher (> 10%), even when the *H. pylori* infection rate was lower (35.6%), the OR of colorectal adenoma with *H. pylori* infection was significantly increased (Group 4: OR: 1.52, 95% CI 1.46-1.57). This means that the DM prevalence rate might be the key factor of increased colorectal adenoma risk with *H. pylori* infection.

Our previous study demonstrated the interaction of hyperglycemia and *H. pylori* infection in colon adenoma formation. We found that the OR for adenoma was 1.437 (95% CI 1.197–1.726) if *H. pylori* was present or 1.629 (95% CI 1.239–2.14) if $HbA_{1c} \geq 6.5$. When combining these two factors, the OR was elevated to 4.712 (95% CI 3.189–6.963), suggesting that these two factors may have a synergistic effect in colorectal adenoma [19]. The likely reason for the synergistic effect may involve several processes. First, hyperglycemia status affected gastrointestinal morphology and function and resulted in gut barrier loss and changes in intestinal mucosa permeability. Second, high-fat and high-caloric diets also increase gut permeability, and this situation was more significant in DM patients [75]. Third, some intestinal microorganism-related products, such as lipopolysaccharides, would more efficiently pass through the gut barrier and stimulate the Toll-like receptors in the mucosa. This would trigger a serious inflammatory process, and finally, IL-17 and IL-6 will increase. IL-17 activates the signal transducer and activator of the transcription 3 pathway, promoting cell proliferation and survival and finally inducing tumorigenesis [76].

These animal models and individualized study results support this study finding that states that an elevated DM prevalence rate enhances the risk of colorectal adenoma in *H. pylori*-infected populations. Our study still had several limitations. First, in our subgroup analysis, we found that the Group 2 studies had more heterogeneity. The reason for this condition may be related to population studies with differences in study location, population, aging, and gender. Despite this heterogeneity, *H. pylori* infection also increased the risk of colorectal adenoma. Second, the asymmetry of the results of Egger's test and funnel plots suggested the possibility of publication bias. However, because most of our included studies [3,6,8,9,19, 21-42] had statistically significant results, Egger's test and funnel plots would show asymmetry. Third, the population DM prevalence rate might not completely represent our included studies participant's diabetes condition. Only Lin et al. [24] and Hu et al. [19] included the DM prevalence rate in their studies. To the best of our knowledge, we tried to estimate the diabetes rate of each study as accurately as possible.

Conclusion

In conclusion, our study demonstrated that population DM prevalence affects the risk of colorectal adenoma with *H. pylori* infection. Since diabetes prevalence was over 6% in the background study population, *H. pylori* infection became a more significant factor in inducing colorectal adenoma formation. Given the increasing prevalence of diabetes in the world, *H. pylori* eradication and hyperglycemia control might have an impact on the prevention of colorectal neoplasm formation.

List Of Abbreviations

H. pylori: *Helicobacter pylori*

HbA_{1c} : glycosylated hemoglobin

DM: diabetes mellitus

CRC: colorectal carcinoma

CI: confidence intervals

OR: odds ratio

Declarations

Ethics approval and consent to participate: Not applicable

Consent for publication: Not applicable

Availability of data and material: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: MMH-108-31. The funding was provided by Department of Medical Research, Mackay memorial hospital, for encouraging members to carry out clinical studies. After reviewing the proposals and approving the promising studies, the funding body will not intervene in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript in any way.

Author contributions: MJC, MSW and HWY acquisition of data; CCC, CJL, SCS analysis and interpretation of data; YCL, LYY, YCK interpretation and analysis of data, revising the article; CTH and HYW for prevalence of diabetes survey and interpretation of data, revising the article; KCH conception and design of the

study, critical revision, final approval. All authors read and approved the final manuscript.

Acknowledgements: Departments of Medical Research, MacKay Memorial Hospital, Taipei

References

1. **Muhammad JS**, Zaidi SF, Sugiyama T. Epidemiological ins and outs of *helicobacter pylori*: a review. *J Pak Med Assoc* 2012; **62**: 955-959 [PMID: 23139983]
2. IARC Monogr Eval Carcinog Risks. *Hum* 1994; **61**: 177–240 [PMID: 7715070]
3. **Sonnenberg A**, Genta, RM. *Helicobacter pylori* is a risk factor for colonic neoplasms. *AM J Gastroenterol* 2013; **108**: 208-215 [PMID: 23208272 DOI: 10.1038/ajg.2010.407]:
4. **Rokkas T**, Sechopoulos P, Pistiolas D, Kothonas F, Margantinis G, Kouklulis G. The relationship of *Helicobacter pylori* infection and colon neoplasia, on the basis of meta-analysis. *Eur J Gastroenterol Hepatol* 2013; **25**: 1286-1294 [PMID: 23820245]
5. **Kapetanakis N**, Kountouras J, Zayos C, Michael S, Tsarouchas G, Gavalas E, Anastasiadou K, Tsiaousi E, Venizelos I, Nikolaidou C, Vardaka E, Kouklakis G, Moschos I. *Helicobacter pylori* infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. *Am J Epidemiol* 2012; **176**: 566-567 [PMID: 22908208 DOI: 10.1093/aje/kws302]
6. **Liou JM**, Lin JW, Huang SP, Lin JT, Wu MS. *Helicobacter pylori* infection is not associated with increased risk of colorectal polyps in Taiwanese. *Int J Cancer* 2006; **119**: 1999-2000 [PMID: 16708392 DOI: 10.1002/ijc.22050]
7. **Machida-Montani A**, Sasazuki S, Inoue M, Natsukawa S, Shaura K, Koizumi Y, Kasuda Y, Hanaoka T, Tsugane S. Atrophic gastritis, *Helicobacter pylori*, and colorectal cancer risk: A case-control study. *Helicobacter* 2007; **12**: 328-32 [PMID: 17669106]
8. **Nam KW**, Baeg MK, Kwon JH, Cho SH, Na SJ, Choi MG. *Helicobacter pylori* seropositivity is positively associated with colorectal neoplasms. *Korean J Gastroenterol* 2013; **61**: 259-64 [PMID: 23756667]
9. **Inoue I**, Mukoubayashi C, Yoshimura N, Niwa T, Deguchi H, Watanabe M, Enomoto S, Maekita T, Ueda K, Iquchi M, Yanaoka K, Tamai H, Arjj K, Oka M, Fujishiro M, Takeshita T, Iwane M, Mohara O, Ichinose M. Elevated risk of colorectal adenoma with *Helicobacter pylori*-related chronic gastritis: A population-based case-control study. *Int J Cancer* 2011; **129**: 2704-2711 [PMID: 21225622 DOI: 10.1002/ijc.25931]
10. **Plummer M**. *Helicobacter pylori* and Colonic Neoplasms. *AM J Gastroenterol* 2013; **108**: 216-217 [PMID: 23381070 DOI: 10.1038/ajg.2012.409]
11. **Chen YS**, Xu SX, Ding YB, Huang XE, Deng B. *Helicobacter pylori* infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. *Asian Pac J Cancer Prev* 2013; **14**: 7613-7619 [PMID: 24460342]
12. **Wu Q**, Yang ZP, Xu P, Gao LC, Fan DM. Association between *Helicobacter pylori* infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. *Colorectal Dis* 2013; **15**: e352-e364 [PMID: 23672575 DOI: 10.1111/codi.12284]
13. **Rokkas T**, Sechopoulos P, Pistiolas D, Kothonas F, Margantinis G, Kouklulis G. The relationship of *Helicobacter pylori* infection and colon neoplasia, on the basis of meta-analysis. *Eur J Gastroenterol Hepatol* 2013; **25**: 1286-1294 [PMID: 23820245]
14. **Guariguata L**, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract* 2014; **103**: 137-149 [PMID: 24630390]
15. **American Diabetes Association**. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010; **33**: S62–9
16. **Ramachandran A**, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. *World J Diabetes* 2012; **3**: 110-117 [PMID: 22737281 DOI: 10.4239/wjd.v3.i6.110]
17. **Eddi R**, Karki A, Shah A, DeBari VA, DePasquale JR. Association of type 2 diabetes and colon adenomas. *J Gastrointest Cancer* 2012; **43**: 87-92 [PMID: 21894459]
18. **Yuhara H**, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? *Am J Gastroenterol* 2011; **106**: 1911-1921 [PMID: 21912438 DOI: 10.1038/ajg.2011.301]
19. **Hu KC**, Wu MS, Chu CH, Wang HY, Lin SC, Liu SC, Liu CC, Su TH, Chen TH, Chen CL, Liu CJ, Shih SC. Synergistic effect of hyperglycemia and *Helicobacter pylori* infection status on colorectal adenoma risk. *J Clin Endocrinol Metab* 2017; **102**: 2017-00257. [PMID: 28475740 DOI: 10.1210/jc.2017-00257]
20. **Hu KC**, Wu MS, Chu CH, Wang HY, Lin SC, Liu CC, Su TH, Liao WC, Chen CL, Liu CJ, Shih SC. Decreased Colorectal Adenoma Risk after *Helicobacter pylori* Eradication: A Retrospective Cohort Study. *Clin Infect Dis* 2019; **68** (12), 2105-2113. [PMID: 30566695 DOI: 10.1093/cid/ciy591]
21. **Mizuno S**, Morita Y, Inui T, Asakawa A, Ueno N, Ando T, Kato H, Uchida M, Yoshikawa T, Inui A. *Helicobacter pylori* infection is associated with colon adenomatous polyps detected by high-resolution colonoscopy. *Int J Cancer* 2005; **117**: 1058-1059 [PMID: 15986436 DOI: 10.1002/ijc.21280]
22. **Brim H**, Zahaf M, Laiyemo AO, Nouraie M, Pérez-Pérez GI, Smoot DT, Lee E, Ashktorab H. Gastric *Helicobacter pylori* infection associates with an increased risk of colorectal polyps in African Americans. *BMC cancer* 2014; **14**: 296 [PMID: 24774100]
23. **Selgrad M**, Bornschein J, Kandulski A, Hille C, Weigt J, Roessner A, Wex T, Malfertheiner P. *Helicobacter pylori* but not gastrin is associated with the development of colonic neoplasms. *Int J Cancer* 2014; **135**: 1127-1131 [PMID: 24496701 DOI: 10.1002/ijc.28758]
24. **Lin YL**, Chiang JK, Lin SM, Tseng CE. *Helicobacter pylori* infection concomitant with metabolic syndrome further increase risk of colorectal adenomas. *World J Gastroenterol* 2010; **16**: 3841-3846 [PMID: 20698048]
25. **Hong SN**, Lee SM, Kim JH, Lee TY, Kim JH, Choe WH, Lee SY, Cheon SY, Sung YK, Park HS, Shim CS. *Helicobacter pylori* infection increases the risk of colorectal adenomas: cross-sectional study and meta-analysis. *Dig Dis Sci* 2012; **57**: 2184-2194. [PMID: 22669208]

26. **Aydin A**, Karasu Z, Zeytinoglu A, Kumanlioglu K, Özacar T. Colorectal adenomateous polyps and *Helicobacter pylori* *Am J Gastroenterol* 1999; **94**: 1121-1122 [PMID: 10201512]
27. **Siddheshwar RK**, Muhammad KB, Gray JC, Kelly SB. Seroprevalence of *Helicobacter pylori* in patients with colorectal polyps and colorectal carcinoma. *Am J Gastroenterol* 2001; **96**: 84-88 [PMID: 11197293]
28. **Fujimori S**, Kishida T, Kobayashi T, Sekita Y, Seo T, Nagata K, Yamashita K, Ohaki Y, Sakamoto C. *Helicobacter pylori* infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women. *J Gastroenterol* 2005; **40**: 887-893 [PMID:16211345]
29. **Bae RC**, Jeon S W, Cho HJ, Jung MK, Kweon YO, Kim SK. Gastric dysplasia may be an independent risk factor of an advanced colorectal neoplasm. *World J Gastroenterol* 2009; **15**: 5722–5726 [PMID: 19960571]
30. **Abbass K**, Gul W, Beck G, Markert R, Akram S. Association of *Helicobacter pylori* infection with the development of colorectal polyps and colorectal carcinoma. *South Med J* 2011; **104**: 473–476 [PMID: 21886044]
31. **Shmueli H**, Melzer E, Braverman M, Domniz N, Yahav J. *Helicobacter pylori* infection is associated with advanced colorectal neoplasia. *Scand J Gastroenterol* 2014; **49**: 35-42 [PMID: 24490722]
32. **Breuer-Katschinski B**, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell, H. *Helicobacter pylori* and the risk of colonic adenomas. *Digestion* 1999; **60**: 210-215 [PMID: 10343134 DOI: 10.1159/000007661]
33. **Georgopoulos SD**, Polymeros D, Triantafyllou K, Spiliadi C, Mentis A, Karamanolis DG, Ladas SD. Hypergastrinemia is associated with increased risk of distal colon adenomas. *Digestion* 2006; **74**: 42-46 [PMID:17068397]
34. **Buso AG**, Rocha H L O G, Diogo DM, Diogo P M, Diogo-Filho A. Seroprevalence of *Helicobacter pylori* in patients with colon adenomas in a Brazilian university hospital. *Arq Gastroenterol* 2009; **46**: 97-101 [PMID: 19578608]
35. **Kim TJ**, Kim ER, Chang DK, Kim YH, Baek SY, Kim K, Hong SN. *Helicobacter pylori* infection is an independent risk factor of early and advanced colorectal neoplasm. *Helicobacter* 2017; **22** [PMID: 28124492 DOI: 10.1111/hel.12377]
36. **Nam JH**, Hong CW, Kim BC, Shin A, Ryu KH, Park BJ, Kim B, Sohn DK, Han KS, Kim J, Lee CW. *Helicobacter pylori* infection is an independent risk factor for colonic adenomatous neoplasms. *Cancer Causes Control* 2017; **28**: 107-115 [PMID: 28025763]
37. **Yan Ye**, Chen YN, Zhao Q, Chen C, Lin CJ, Jin Y, Pan S, Wu JS. *Helicobacter pylori* infection with intestinal metaplasia: An independent risk factor for colorectal adenomas. *World J Gastroenterol* 2017; **23**: 1443-1449 [PMID: 28293091]
38. **Park YM**, Kim HS, Park JJ, Baik SJ, Youn YH, Kim JH, Park H. A simple scoring model for advanced colorectal neoplasm in asymptomatic subjects aged 40-49 years. *BMC Gastroenterol* 2017; **17** [PMID: 28068908 DOI: 10.1186/s12876-016-0562-9]
39. **Lee JY**, Park HW, Choi JY, Lee JS, Koo JE, Chung EJ, Chang HS, Choe J, Yang DH, Myung SJ, Jung HY, Yang SK, Byeon JS. *Helicobacter pylori* infection with atrophic gastritis is an independent risk factor for advanced colonic neoplasm. *Gut Liver* 2016; **10**: 902-909 [PMID: 27458180 DOI: 10.5009/gnl15340]
40. **Tongtawe T**, Kaewpitoon S, Kaewpitoon N, Dechsukhum C, Leeanansaksiri W, Loyd RA. *Helicobacter pylori* associated gastritis increases risk of colorectal polyps: a hospital based-cross-sectional study in Nakhon Ratchasima Province, Northeastern Thailand. *Asian Pac J Cancer Prev* 2016; **17**: 341-345 [PMID: 26838234]
41. **Zuniga R**, Bautista J, Sapra K, Westerfield K, Williams S, Sy AM. Combination of Triple Therapy and Chronic PPI Use May Decrease Risk of Colonic Adenomatous Polyps in *Helicobacter pylori* *Gastroenterol Res Pract* 2015; **2015**: 638547 [PMID: 26064095]
42. **Patel S**, Lipka S, Shen H, Barnowsky A, Silpe J, Mosdale J, Viswanathan P, Mustacchia P, Krishnamachar B. The association of *pylori* and colorectal adenoma: does it exist in the US Hispanic population? *J Gastrointest Oncol* 2014; **5**: 463-8 [PMID: 25436126]
43. **Charvat H**, Goto A, Goto M, Inoue M, Heianza Y, Arase Y, Tuomilehto J, Tsugane S, Noda M, Inoue M. Impact of population aging on trends in diabetes prevalence: A meta-regression analysis of 160,000 Japanese adults. *J diabetes investing* 2015; **6**: 533-542 [PMID: 26417410 DOI: 10.1111/jdi.12333]
44. **Menke A**, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. *JAMA* 2015; **314**: 1021-1029 [PMID: 26348752]
45. **Whiting DR**, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract* 2011; **94**: 311-321 [PMID: 22079683]
46. **Jiang YD**, Chang CH, Tai TY, Chen JF, Chuang LM. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000–2009 Nationwide Health Insurance database. *J Formos Med Assoc* 2012; **111**: 599-604 [PMID: 23217595]
47. **Guariguata L**, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract* 2014; **103**: 137-149 [PMID: 24630390]
48. **Satman I**, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, Karsidag K, Kalaca S, Ozcan C, King H. .Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). *Diabetes care* 2002; **25**: 1551-1556 [PMID: 12196426]
49. **Imkampe AK**, Gulliford MC. Increasing socio-economic inequality in type 2 diabetes prevalence—repeated cross-sectional surveys in England 1994–2006. *Eur J Public Health* 2010; **21** : 484-490 [PMID: 20685812]
50. **Panagiotakos DB**, Pitsavos C, Chrysoshoou C, Stefanadis C. The epidemiology of Type 2 diabetes mellitus in Greek adults: the ATTICA study. *Diabetic Med* 2005; **22**: 1581-1588 [PMID: 16241925]
51. **International Diabetes Federation**. IDF Diabetes atlas. 7th Edition. 2015. International Diabetes Federation, Brussels. <http://www.idf.org/diabetesatlas/> (accessed Nov 6, 2015).
52. **Frese T**, Sandholzer H, Voigt S, Voigt R. Epidemiology of Diabetes Mellitus in German General Practitioners' Consultation-Results of the SESAM 2-study. *Exp Clin Endocrinol Diabetes* 2008; **116**: 326-328 [PMID: 18700277]

53. **Go MF.** Review article: natural history and epidemiology of *Helicobacter pylori* *Aliment Pharmacol Ther* 2002; **16** Suppl 1: 3-15 [PMID: 11849122 DOI: 10.1046/j.1365-2036.2002.0160s1003.x]
54. **Marshall BJ, Warren JR.** Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; **1**: 1311-1315 [PMID:6145023]
55. **Hooi JK, Lai WY, Ng WK, Suen MM, Underwood FE, Tanyingoh D, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC.** Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *Gastroenterology* 2017; **153**: 420-429 [PMID: 28456631]
56. **Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY.** Association between *Helicobacter pylori* eradication and gastric cancer incidence: a systematic review and meta-analysis. *Gastroenterology* 2016; **150**: 1113-1124. e5 [PMID: 26836587 DOI: 10.1053/j.gastro.2016.01.028]
57. **Bravo D, Hoare A, Soto C, Valenzuela MA, Queset AF.** *Helicobacter pylori* in human health and disease: Mechanisms for local gastric and systemic effects. *World J Gastroenterol* 2018; **24**:3071-3089 [PMID: 30065554]
58. **Ražuka-Ebela D, Giupponi B, Franceschi F.** *Helicobacter pylori* and extragastric diseases. *Helicobacter* 2018; **Supp 1** [DOI: 10.1111/hel.12520]
59. **Butt J & Epplein M.** *Helicobacter pylori* and colorectal cancer—A bacterium going abroad?. *PLoS pathogens*, 2019, 15.8: e1007861 [PMID: 31393968; DOI: 10.1371/journal.ppat.1007861]
60. **NCD Risk Factor Collaboration.** Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. *The Lancet* 2016; **387**: 1513-1530 [DOI: 10.1016/S0140-6736(16)00618-8]
61. **Wandell PE, Carlsson AC.** Gender differences and time trends in incidence and prevalence of type 2 diabetes in Sweden—a model explaining the diabetes epidemic worldwide today? *Diabetes Res Clin Pract* 2014; **106**: e90–92 [PMID: 25451899]
62. **American Diabetes Association.** Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2012; **35** Suppl 1: 64–71 [PMID:]
63. **Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA.** Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer ? *Am J Gastroenterol* 2011; **106**: 1911-1921 [PMID: 21912438]
64. **Koster I, Schubert I, Huppertz E.** Follow up of the CoDiM-Study: cost of diabetes mellitus 2000–2009. *Dtsch Med Wochenschr* 2012; **137**:1013–1016 [PMID: 22549261]
65. **Schunk M, Reitmeir P, Schipf S, Muller G, Ellert U, Neuhauser H, Tamayo T, Rathmann W, Holle R.** Health-related quality of life in subjects with and without Type 2 diabetes: pooled analysis of five population-based surveys in Germany. *Diabet Med* 2012; **29**:646–653 [PMID: 21978176]
66. **Hwang CK, Han PV, Zabetian A, Ali MK, Narayan KM.** Rural diabetes prevalence quintuples over twenty-five years in low- and middle-income countries: a systematic review and meta-analysis. *Diabetes Res Clin Pract* 2012; **96**: 271–85 [PMID: 22261096]
67. **Zuo H, Shi Z, Hussain A.** Prevalence, trends and risk factors for the diabetes epidemic in China: a systematic review and meta-analysis. *Diabetes Res Clin Pract* 2014; **104**: 63–72 [PMID: 24468097 DOI: 10.1016/j.diabres.2014.01.002]
68. **Jayawardena R, Ranasinghe P, Byrne NM, Soares MJ, Katulanda P, Hills AP.** Prevalence and trends of the diabetes epidemic in South Asia: a systematic review and meta-analysis. *BMC Public Health* 2012; **12**: 380 [PMID: 22630043]
69. **Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccak N, Karsidag K, Genc S, Telci A .** Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. *Eur J Epidemiol* 2013; **28**: 169–80 [PMID: 23407904]
70. **Alharbi NS, Almutari R, Jones S, Al-Daghri N, Khunti K, de Lusignan S.** Trends in the prevalence of type 2 diabetes mellitus and obesity in the Arabian Gulf States: systematic review and meta-analysis. *Diabetes Res Clin Pract* 2014; **106**: e30–33 [PMID: 25241351]
71. **Menke A, Casagrande S, Geiss L, Cowie CC.** Prevalence of and trends in diabetes among adults in the United States, 1988–2012. *JAMA* 2015; **314**: 1021–29 [PMID: 26348752]
72. **Imkampe AK, Gulliford MC.** Increasing socio-economic inequality in type 2 diabetes prevalence—repeated cross-sectional surveys in England 1994–2006. *Eur J Public Health* 2011; **21**: 484–90 [PMID: 20685812 DOI: 10.1093/eurpub/ckq 106]
73. **Icks A, Moebus S, Feuersenger A, Haastert B, Jockel KH, Giani G.** Diabetes prevalence and association with social status—widening of a social gradient? German national health surveys 1990–1992 and 1998. *Diabetes Res Clin Pract* 2007; **78**: 293–97 [PMID: 17532522]
74. **Teuscher AU, Diem P, Thomas W, Janett J, Teuscher A.** Incidence of insulin-dependent diabetes mellitus in Switzerland (1972–1993) in 19-year-old men. *Schweiz Med Wochenschr* 1995; **125**: 1041–45 [PMID: 7770760]
75. **De Kort S, Keszthelyi D, Masclee AAM.** Leaky gut and diabetes mellitus: what is the link? *Obes Rev* 2011; **12**: 449-458 [PMID: 21382153]
76. **Gallimore AM, Godkin A.** Epithelial barriers, microbiota, and colorectal cancer. *N Engl J Med* 2013; **368**: 282-284 [PMID: 23323906 DOI: 10.1056/NEJMcibr1212341]

Table 1

Table 1 Demographics and outcome characteristics of included Group 1 to group 4 studies

st author	Study duration	Study location	Study design	<i>H. pylori</i> detection	Sample size	Mean age (years)	Gender (% male)	Odds ratio*	95% CI	<i>H. pylori</i> infection rate (%) [#]	Estimate DM prevalence (%)	DM prevalence Reference	Ref
Group 1 (DM prevalence < 6%)													
Adheshwar	1997-1999	UK	Cross-section	Serology	236	62.21	44.92	1.08	0.58 - 1.99	35.5	4.3	49	27
Chiu JM	2005	Taiwan	Cross-section	UBT(C13)	462	49.97	57.79	1.06	0.69 - 1.62	53.9	5.56	46	6
de AG	2005-2007	Brazil	Case-control	Serology	188	59.79	46.88	1.98	0.82 - 3.15	71.2	5.8	45	34
Group 2 (DM prevalence: 6 ~ 8 %)													
Chen YL	2004-2006	Taiwan	Cross-section	CLO test	9311	52.84	41.95	1.366	1.23 - 1.517	53.9	6.94	24	24
Christopoulos D	2000-2001	Greece	Case-control	Serology	156	64.25	NA	1.83	0.88 - 3.78	52.1	7	51	33
Imori S	1996-2003	Japan	Cross-section	UBT and CLO	669	61.08	70.25	1.6	1.18 - 2.12	51.7	7.07	50	28
Ishiguro T	1996-2004	Japan	Case-control	Serology	478	49.7	100	2.26	1.44 - 3.55	51.7	7.07	50	9
Itzhaki S, H	2008-2010	Israel	Cross-section	Serology	273	64.5	NA	4.07	2.26 - 7.35	68.9	7.1	47	31
Kim A	1996-1997	Turkey	Cross-section	Serology	267	49.13	45.32	2.63	1.26 - 5.48	77.2	7.2	48	26
Kuehlschmidt A	1993-1996	Germany	Case-control	Serology	196	62.4	NA	2.1	1.1 - 3.9	35.3	7.2	53	32
Kuroki T	2005	Japan	Cross-section	Serology	305	59.8	57.33	3.4	1.9 - 6.08	51.7	7.45	43	21
Group 3 (DM prevalence: 8 ~ 10 %)													
Leung T	2014-2015	Thailand	Cross-section	Pathology	303	NA	38.28	7.29	2.74-19.36	43.6	8	52	40
Lee RC	2005-2008	Korea	Case-control	UBT and CLO	346	54.1	74.57	1.037	0.67 - 1.59	54.0	8.6	45	29
Lim TJ	2002-2010	Korea	Cross-section	Serology	8916	51.6	100.00	1.37	1.18 - 1.58	54.0	8.6	45	35
Lim JH	2007-2009	Korea	Case-control	CLO	4466	NA	53.63	1.28	1.11 - 1.47	54.0	8.6	45	36
Lim JY	2012-2013	Korea	Cross-section	Serology	6351	51.7	52.79	1.28	1.09-1.36	54.0	8.9	45	39
Lim SN	2010	Korea	Cross-section	Serology	2195	49.23	62.00	1.36	1.1 - 1.68	54.0	9	47	25
Lim YM	2008-2012	Korea	Cross-section	Serology	2781	44.8	58.72	2.26	1.11-4.62	54.0	9.0	47	38
Lim KW	2004-2005	Korea	Cross-section	Serology	598	56.23	65.38	1.93	1.24 - 3.01	54.0	8.8	45	8

KC	2006-2015	Taiwan	Cross-section	CLO	2475	52.90	66.91	1.44	1.20 -1.73	53.9	9.59	19	19
Group 4 (DM prevalence: > 10 %)													
Yan Ye	2014-2016	China	Cross-section	UBT	1641	50.73	66.24	1.535	1.04 -1.75	55.8	10.6	52	37
Nam JH	2005-2009	USA	Cross-section	pathology	1256	57	34.00	1.5	1.2 - 2.2	35.6	10.7	44	22
Grad M	2008-2013	Germany	Cross-section	Serology	377	66.38	50.13	1.85	1.14 - 2.99	35.3	11.9	47	23
Sonnenberg	2008-2011	USA	Cross-section	pathology	22231	57.8	41.00	1.52	1.46 -1.57	35.6	12.1	44	3
Bass K	2008-2009	USA	Cross-section	CLO	192	59.1	38.02	1.29	0.69 - 2.42	35.6	12.1	44	30
Del S	2009-2011	USA	Case-control	Pathology	798	54.82	NA	1.04	0.67-1.61	35.6	12.1	44	42
Singh R	2010-2012	USA	Case-control	NA	943	57	NA	1.55	1.13-2.12	35.6	12.3	44	41

OR ratio: for colorectal adenoma; # from reference 57; Siddheshwar RK study only included colon polyp population; Nam JH, Tongtawee S. only demonstrated aging disturbance;

Yan Ye YM focus age 40-49 subjects; Sonnenberg only included subjects who had *H. pylori* pathology report

Figures

Figure 1

Flow diagram of the studies identified in this meta-analysis

Figure 2

Forest plot showing individual and pooled odds ratio [95% confidence intervals (CIs)] of all studies included with subgroups of the prevalence of DM. Each study is labeled with the authors' name.

Figure 3

(A) Funnel plot of all studies included examining the relation between *Helicobacter pylori* infection and colon adenoma. (B) Egger's regression test of all studies including the relation between *Helicobacter pylori* infection and colon adenoma.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [20190402Appendix.docx](#)
- [PRISMA2009checklist20190301.pdf](#)